Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Chan Y. Cheah, Kate Burbury, Jane F. Apperley, Francoise Huguet, Vincenzo Pitini, Martine Gardembas, David Ross, Donna Forrest, Philippe Genet, Philippe Rousselot, Nigel Patton, Graeme Smith, Cynthia E. Dunbar, Sawa Ito, Ricardo C.T. Aguiar, Olatoyosi Odenike, Alla Gimelfarb, Nicholas C.P. Cross, John F. Seymour

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms. Patients are typically male, with morphologic features of a Philadelphia-negative chronic myeloproliferative syndrome or chronicmyelomonocytic leukemia with eosinophilia. Reciprocal translocations involving PDGFRB result in fusion genes with constitutively activated receptor tyrosine kinase sensitive to inhibition with imatinib. We present an updated and expanded analysis of a cohort of 26 such patients treated with imatinib. After a median follow-up of 10.2 years (range, 1.8-17 years), the 10-year overall survival rate was 90% (95% confidence interval, 64%-97%); after median imatinib duration of 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88% (95% confidence interval, 65%-96%). Of the patients, 96% responded; no patients who achieved a complete cytogenetic (n = 13) or molecular (n = 8) remission lost their response or progressed to blast crisis. Imatinib is well-tolerated and achieves excellent long-term responses in patients with PDGFRB rearrangements.

LanguageEnglish
Pages3574-3577
Number of pages4
JournalBlood
Volume123
Issue number23
DOIs
Publication statusPublished - 5 Jun 2014
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Cheah, C. Y., Burbury, K., Apperley, J. F., Huguet, F., Pitini, V., Gardembas, M., ... Seymour, J. F. (2014). Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 123(23), 3574-3577. https://doi.org/10.1182/blood-2014-02-555607
Cheah, Chan Y. ; Burbury, Kate ; Apperley, Jane F. ; Huguet, Francoise ; Pitini, Vincenzo ; Gardembas, Martine ; Ross, David ; Forrest, Donna ; Genet, Philippe ; Rousselot, Philippe ; Patton, Nigel ; Smith, Graeme ; Dunbar, Cynthia E. ; Ito, Sawa ; Aguiar, Ricardo C.T. ; Odenike, Olatoyosi ; Gimelfarb, Alla ; Cross, Nicholas C.P. ; Seymour, John F. / Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. In: Blood. 2014 ; Vol. 123, No. 23. pp. 3574-3577.
@article{e567ba28da8043dd8003d0f3d9cb836b,
title = "Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib",
abstract = "Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms. Patients are typically male, with morphologic features of a Philadelphia-negative chronic myeloproliferative syndrome or chronicmyelomonocytic leukemia with eosinophilia. Reciprocal translocations involving PDGFRB result in fusion genes with constitutively activated receptor tyrosine kinase sensitive to inhibition with imatinib. We present an updated and expanded analysis of a cohort of 26 such patients treated with imatinib. After a median follow-up of 10.2 years (range, 1.8-17 years), the 10-year overall survival rate was 90{\%} (95{\%} confidence interval, 64{\%}-97{\%}); after median imatinib duration of 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88{\%} (95{\%} confidence interval, 65{\%}-96{\%}). Of the patients, 96{\%} responded; no patients who achieved a complete cytogenetic (n = 13) or molecular (n = 8) remission lost their response or progressed to blast crisis. Imatinib is well-tolerated and achieves excellent long-term responses in patients with PDGFRB rearrangements.",
author = "Cheah, {Chan Y.} and Kate Burbury and Apperley, {Jane F.} and Francoise Huguet and Vincenzo Pitini and Martine Gardembas and David Ross and Donna Forrest and Philippe Genet and Philippe Rousselot and Nigel Patton and Graeme Smith and Dunbar, {Cynthia E.} and Sawa Ito and Aguiar, {Ricardo C.T.} and Olatoyosi Odenike and Alla Gimelfarb and Cross, {Nicholas C.P.} and Seymour, {John F.}",
year = "2014",
month = "6",
day = "5",
doi = "10.1182/blood-2014-02-555607",
language = "English",
volume = "123",
pages = "3574--3577",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

Cheah, CY, Burbury, K, Apperley, JF, Huguet, F, Pitini, V, Gardembas, M, Ross, D, Forrest, D, Genet, P, Rousselot, P, Patton, N, Smith, G, Dunbar, CE, Ito, S, Aguiar, RCT, Odenike, O, Gimelfarb, A, Cross, NCP & Seymour, JF 2014, 'Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib', Blood, vol. 123, no. 23, pp. 3574-3577. https://doi.org/10.1182/blood-2014-02-555607

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. / Cheah, Chan Y.; Burbury, Kate; Apperley, Jane F.; Huguet, Francoise; Pitini, Vincenzo; Gardembas, Martine; Ross, David; Forrest, Donna; Genet, Philippe; Rousselot, Philippe; Patton, Nigel; Smith, Graeme; Dunbar, Cynthia E.; Ito, Sawa; Aguiar, Ricardo C.T.; Odenike, Olatoyosi; Gimelfarb, Alla; Cross, Nicholas C.P.; Seymour, John F.

In: Blood, Vol. 123, No. 23, 05.06.2014, p. 3574-3577.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

AU - Cheah, Chan Y.

AU - Burbury, Kate

AU - Apperley, Jane F.

AU - Huguet, Francoise

AU - Pitini, Vincenzo

AU - Gardembas, Martine

AU - Ross, David

AU - Forrest, Donna

AU - Genet, Philippe

AU - Rousselot, Philippe

AU - Patton, Nigel

AU - Smith, Graeme

AU - Dunbar, Cynthia E.

AU - Ito, Sawa

AU - Aguiar, Ricardo C.T.

AU - Odenike, Olatoyosi

AU - Gimelfarb, Alla

AU - Cross, Nicholas C.P.

AU - Seymour, John F.

PY - 2014/6/5

Y1 - 2014/6/5

N2 - Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms. Patients are typically male, with morphologic features of a Philadelphia-negative chronic myeloproliferative syndrome or chronicmyelomonocytic leukemia with eosinophilia. Reciprocal translocations involving PDGFRB result in fusion genes with constitutively activated receptor tyrosine kinase sensitive to inhibition with imatinib. We present an updated and expanded analysis of a cohort of 26 such patients treated with imatinib. After a median follow-up of 10.2 years (range, 1.8-17 years), the 10-year overall survival rate was 90% (95% confidence interval, 64%-97%); after median imatinib duration of 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88% (95% confidence interval, 65%-96%). Of the patients, 96% responded; no patients who achieved a complete cytogenetic (n = 13) or molecular (n = 8) remission lost their response or progressed to blast crisis. Imatinib is well-tolerated and achieves excellent long-term responses in patients with PDGFRB rearrangements.

AB - Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms. Patients are typically male, with morphologic features of a Philadelphia-negative chronic myeloproliferative syndrome or chronicmyelomonocytic leukemia with eosinophilia. Reciprocal translocations involving PDGFRB result in fusion genes with constitutively activated receptor tyrosine kinase sensitive to inhibition with imatinib. We present an updated and expanded analysis of a cohort of 26 such patients treated with imatinib. After a median follow-up of 10.2 years (range, 1.8-17 years), the 10-year overall survival rate was 90% (95% confidence interval, 64%-97%); after median imatinib duration of 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88% (95% confidence interval, 65%-96%). Of the patients, 96% responded; no patients who achieved a complete cytogenetic (n = 13) or molecular (n = 8) remission lost their response or progressed to blast crisis. Imatinib is well-tolerated and achieves excellent long-term responses in patients with PDGFRB rearrangements.

UR - http://www.scopus.com/inward/record.url?scp=84902168976&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-02-555607

DO - 10.1182/blood-2014-02-555607

M3 - Article

VL - 123

SP - 3574

EP - 3577

JO - Blood

T2 - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -